Comparison
Dulaglutide vs. Triptorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
923950-08-7
57773-63-4
Molecular weight
59670 g/mol
1311.45 g/mol
Half-life
110 h
3 h
Sequence
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcpGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Mechanism of action
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
4
of which in humans
5
4
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
2
3